What's in American Research Corporation's pipeline?

American Research Corporation has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with American Research Corporation's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/american-research-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

American Research Corporation — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

American Research Corporation pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	marketed	HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase	Virology / Hepatology

Therapeutic area mix

Virology / Hepatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for American Research Corporation:

Cite this brief

Drug Landscape (2026). American Research Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/american-research-corporation. Accessed 2026-05-16.